Arcus Biosciences Inc., of Hayward, Calif., said it closed its IPO of 8 million shares of common stock at $15 each, with the underwriters also exercising in full their overallotment option to purchase 1.2 million additional shares. The total gross proceeds are expected to be $138 million.